Squamous Cell Carcinoma of the Anus
8
1
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
The Self-Sampling Pilot Study
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
PEN-866 in Patients With Advanced Solid Malignancies
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer